Targovax announces that TG02 has passed the initial safety review in the first-in-man clinical trial in colorectal cancer
December 18, 2017 01:01 ET
|
Targovax ASA
Oslo, Norway, 18 December 2017 - Targovax ASA (OSE: TRVX), a clinical stage company focused on developing immuno-oncology therapies to target solid tumors, today announces that TG02 has passed the...
Targovax to present at DNB healthcare conference
December 13, 2017 01:00 ET
|
Targovax ASA
Oslo, Norway, 13 December 2017 - Targovax ASA (OSE: TRVX), a clinical stage company focused on developing immuno-oncology therapies to target solid tumors, announces that members of its senior...
Targovax announces that first combination trials with ONCOS-102 have passed their initial, planned, independent safety reviews
December 11, 2017 01:01 ET
|
Targovax ASA
Oslo, Norway, 11 December 2017 - Targovax ASA (OSE: TRVX), a clinical stage company focused on developing immuno-oncology therapies to target solid tumors, announces that clinical trials investigating...
Targovax ASA: New member of the board of directors
November 30, 2017 08:04 ET
|
Targovax ASA
Oslo, Norway, 30 November 2017 - Targovax ASA (OSE: TRVX), a clinical stage company focused on developing immuno-oncology therapies to target solid tumors, announces that the extraordinary general...
Targovax to present at upcoming investor conferences
November 14, 2017 01:01 ET
|
Targovax ASA
Oslo, Norway, 14 November 2017 - Targovax ASA (OSE: TRVX), a clinical stage company focused on developing immuno-oncology therapies to target solid tumors, announces that members of its senior...
Targovax ASA: Notice of Extraordinary General Meeting
November 07, 2017 05:40 ET
|
Targovax ASA
An Extraordinary General Meeting of Targovax ASA will be held at the Company's offices at Lysaker, on 30 November 2017 at 13:00 CET. Please find the notice including agenda for the Extraordinary...
Targovax ASA: Exercise of employee share options and restricted stock units in Targovax ASA
November 03, 2017 05:38 ET
|
Targovax ASA
Reference is made to Targovax ASA's (the "Company") stock exchange notice of 27 October 2017 relating to the board of director's resolutions to increase the share capital in connection with exercise...
Targovax ASA: Third quarter 2017 results
November 02, 2017 02:01 ET
|
Targovax ASA
Oslo, Norway, 2 November 2017 - Targovax ASA (OSE: TRVX), a clinical stage company focused on developing immuno-oncology therapies to target solid tumors, today announces its third quarter 2017...
Targovax ASA: Resolutions to increase the share capital in Targovax ASA in relation to exercise of employee options and settlement of restricted stock units
October 27, 2017 01:01 ET
|
Targovax ASA
The board of directors of Targovax ASA (the "Company") has on 27 October 2017, in accordance with the authorisations granted by the general meeting on 5 April 2017, resolved: - to increase the share...
Targovax ASA: Invitation to third quarter 2017 results presentation Thursday 2 November
October 24, 2017 01:00 ET
|
Targovax ASA
Oslo, Norway, 24 October 2017 - Targovax ASA (OSE: TRVX), a clinical stage company focused on developing immuno-oncology therapies to target solid tumors, will announce its third quarter 2017...